Standing Up To Powerful Interests You are hereHome > Report: Fighting The High Cost Of Rx Drugs Top 20 Pay-For-Delay Drugs How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers Released by: OSPIRG Release date: Thursday, July 11, 2013 > Read News Release> Download Report (PDF) Too often, consumers are forced to shoulder a heavy financial burden, or even go without needed medicine, due to the high cost of brand-name drugs. Our research indicates that one significant cause is the practice called “pay for delay,” which inflates the drug prices paid by tens of millions of Americans.
In a pay-for-delay deal, a brand-name drug company pays off a would-be competitor to delay it from selling a generic version of the drug. Without any competition, the brand-name company can continue demanding high prices for its drug.
This list of 20 drugs known to be impacted by pay-for-delay deals represents the tip of the iceberg. Annual reports by the Federal Trade Commission (FTC) indicate that generic versions of as many as 142 brand-name drugs have been delayed by pay-for-delay arrangements between drug manufacturers since 2005.
However, because the details of these deals rarely become public, consumers have largely been kept in the dark about the extent of the problem. Information about these twenty specific drugs affected by pay-for-delay deals has been made public thanks to legal challenges brought by the FTC, consumer class action lawsuits, research by legal experts, and public disclosures by drug makers.
Key findings of our analysis of these 20 drugs impacted by pay-for-delay deals:
This practice has held back generic medicines used by patients with a wide range of serious or chronic conditions, ranging from cancer and heart disease, to depression and bacterial infection.These payoffs have delayed generic drugs for five years, on average, and as long as nine years.These brand-name drugs cost 10 times more than their generic equivalents, on average, and as much as 33 times more.Combined, these brand-name drug companies have made an estimated $98 billion in total sales of these drugs while the generic versions were delayed. Search form Search AboutIssues21st Century TransportationGetting faster and more reliable trains for Oregon.Close Corporate Tax LoopholesMaking corporations pay the taxes they owe.Consumer ProtectionLooking out for consumers, from bank fees to toxic toys.Health Insurance Rate Watch ProjectMaking insurers accountable and scrutinizing rate hikes.Making Health Care Work for OregonEnsuring that the exchange allows consumers to negotiate for cheaper health care plans.REINING IN WALL STREETStanding up for consumers against reckless banking and financial practices.Stop Subsidizing ObesityEnding wasteful agricultural subsidies for junk food.Reclaim DemocracyStanching the flow of special interest money in our elections.No Secret Money In SalemBringing accountability to economic development subsidies.Act NowJobsDonateNewsroom Tools & Resources
TOY SAFETYProtect your family and see what hidden hazards to watch out for. 
Beat High Bank Fees A Consumer Guide to Shopping Around 
The Young Person's Guide To Health Insurance Building a successful health insurance exchange for Oregon consumers and businesses OSPIRG Get our RSS feed Our Affiliates Are you a student?Our sister (c)(3)Our Federation Archives BlogMedia HitsNews ReleasesReportsResourcesResults Sign UpDonateJoin UsPRIORITY ACTION Take our quick survey to let us know who your health insurer is, and we'll make sure you're the first to know when they propose a rate hike — and give you a chance to speak up.
Join our network and stay up to date on our campaigns, get important consumer updates, and take action on critical issues.
HOMEPAGEABOUT USSTAFFCONTACT USNEWSREPORTS DONATEPRIVACY POLICYACTION CENTERJOBS & INTERNSHIPS OREGON STATE PUBLIC INTEREST RESEARCH GROUP1536 SE 11th Ave., Suite A
Portland, OR 97214 | (503) 231-4181 Like UsFollow UsContact /* Site Analytics code start *//* Site Analytics code end */
No comments:
Post a Comment